Extended Data Fig. 4. Projected number of hospitalizations averted (million) for each fractional-dose strategy as compared to the status quo strategy (i.e., no vaccination) in India.

The estimation examines a wide range of possible transmission (with Re increasing from 1.1 to 8) and vaccine efficacy (Supplementary Table 2) scenarios. Given each Re, the vaccine efficacy (VE) against infection and VE against symptomatic disease are considered as 52% and 79% in the top row, 63% and 82% in the middling row, and 72% and 99% in the bottom row in each subpanel.